Overview

Lipiflow Treatment Alone vs. Lipiflow + Dextenza Treatment for Dry Eye Disease

Status:
Recruiting
Trial end date:
2021-02-01
Target enrollment:
Participant gender:
Summary
To evaluate the benefit of treatment with a physician administered intracanalicular dexamethasone insert in evaporative dry eye disease (DED) patients with meibomian gland disfunction (MGD) and underlying inflammation undergoing LipiFlow Thermal Pulsation.
Phase:
Phase 4
Details
Lead Sponsor:
Eye Surgeons of Indiana
Collaborator:
Ocular Therapeutix, Inc.
Treatments:
Dexamethasone